膀胱尿路上皮癌及尿沉淀细胞P16基因甲基化检测

目的探讨膀胱尿路上皮癌组织及尿沉淀细胞中P16基因启动子的甲基化状况及其临床意义。方法采用甲基化特异性PCR（methylation specific PCR,MSP）的方法检测55例膀胱癌组织及尿沉淀细胞P16基因启动子异常甲基化频率。分析其甲基化程度与膀胱尿路上皮癌临床病理参数之间的关系。结果膀胱尿路上皮癌组织及尿沉淀细胞P16基因甲基化阳性率分别为27.3%（15/55）和21.8%（12/55）;癌组织及尿沉淀细胞P16基因甲基化阳性率差异无统计学意义（P〉0.05）。浸润性和浅表性膀胱尿路上皮癌组织及尿沉淀细胞P16基因甲基化阳性率的差异有统计学意义（P〈0.05）。P16基因甲基化在不同病理分级和不同性别间其差异无统计学意义（P〉0.05）。结论 P16基因甲基化是膀胱尿路上皮癌发生的早期事件,与膀胱尿路上皮癌的浸润性发展相关。尿沉淀细胞P16基因启动子异常甲基化状态可作为无创性诊断膀胱尿路上皮癌并且判断其预后的分子标志物。

Detection of promoter methylation of P16 gene in tumor tissues and urine sediments from bladder urothelial carcinoma

【Objective】 To detect promoter methylation of P16 gene in tissue and urine sediment from bladder urothelial carcinoma patients.【Methods】 A total of 55 patients with bladder urothelial carcinoma was enrolled into this study.The methylation status of P16 gene were detected with methylation specific PCR（MSP） in DNA extracted from tumor tissue and urine sediment in patients.【Results】 Methylation of P16 gene was demonstrated in 27.3% of the tumor tissues,21.8% of the urine sediments,respectively;there was no statistics difference on the methylation status of P16 gene between in tissue and in urine sediment of bladder urothelial carcinoma（P0.05）.The incidence of P16 gene methylation was significantly higher in patients with invasive than superficial bladder urothelial carcinoma（P0.05）.Methylation status of P16 gene had no correlation with gender,tumor grade（P0.05）.【Conclusion】 MSP analysis of P16 gene can be used as a good biomarker for bladder urothelial carcinoma diagnosis,staging and prognosis prediction.